Relation of plasma neuropeptide-Y with myocardial function and infarct severity in acute ST-elevation myocardial infarction
CONCLUSION: High plasma levels of NPY, measured 24h after STEMI, were independently associated with lower LVEF, decreased GLS, larger IS as well as presence of MVO, indicating plasma NPY as a novel clinical risk marker post STEMI.PMID:38555253 | DOI:10.1016/j.ejim.2024.03.027 (Source: European Journal of Internal Medicine)
Source: European Journal of Internal Medicine - March 30, 2024 Category: Internal Medicine Authors: Christina Tiller Martin Reindl Magdalena Holzknecht Ivan Lechner Felix Troger Fritz Oberhollenzer Sebastian von der Emde Thomas Kremser Agnes Mayr Axel Bauer Bernhard Metzler Sebastian J Reinstadler Source Type: research
Relation of plasma neuropeptide-Y with myocardial function and infarct severity in acute ST-elevation myocardial infarction
CONCLUSION: High plasma levels of NPY, measured 24h after STEMI, were independently associated with lower LVEF, decreased GLS, larger IS as well as presence of MVO, indicating plasma NPY as a novel clinical risk marker post STEMI.PMID:38555253 | DOI:10.1016/j.ejim.2024.03.027 (Source: European Journal of Internal Medicine)
Source: European Journal of Internal Medicine - March 30, 2024 Category: Internal Medicine Authors: Christina Tiller Martin Reindl Magdalena Holzknecht Ivan Lechner Felix Troger Fritz Oberhollenzer Sebastian von der Emde Thomas Kremser Agnes Mayr Axel Bauer Bernhard Metzler Sebastian J Reinstadler Source Type: research
Development and validation of a prognostic model for predicting post-discharge mortality risk in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI)
Accurately predicting post-discharge mortality risk in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) remains a complex and critic... (Source: Journal of Cardiothoracic Surgery)
Source: Journal of Cardiothoracic Surgery - March 30, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Lingling Zhang, Zhican Liu, Yunlong Zhu, Mingxin Wu, Haobo Huang, Wenbin Yang, Ke Peng and Jianping Zeng Tags: Research Source Type: research
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
ConclusionAmong adults who underwent first-ever PCI for ACS, ticagrelor use in the DAPT was associated with a lower risk of MOF compared with clopidogrel. Our results support the use of ticagrelor in the DAPT from the perspective of bone health. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 29, 2024 Category: Endocrinology Source Type: research
Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention
CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination...
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Li Ye Sijia Tu Source Type: research
Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention
CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination...
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Li Ye Sijia Tu Source Type: research
Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention
CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination...
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Li Ye Sijia Tu Source Type: research
Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention
CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination...
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Li Ye Sijia Tu Source Type: research
Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention
CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination...
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Li Ye Sijia Tu Source Type: research
Influence of COVID-19 pandemic in India on coronary artery disease clinical presentation, angiography, interventions and in-hospital outcomes: a single centre prospective registry-based observational study
Conclusions
In-hospital mortality among patients with CAD undergoing PCI was significantly higher in the second year of the COVID-19 pandemic in India and could be one of the reasons for excess deaths in the country. These patients had more severe CAD, lower LVEF, and more vasopressor and mechanical support and duration of hospitalisation. (Source: BMJ Open)
Source: BMJ Open - March 29, 2024 Category: General Medicine Authors: Gupta, R., Sharma, K., Khedar, R. S., Sharma, S. K., Makkar, J. S., Natani, V., Bana, A., Sharma, S. Tags: Open access, Cardiovascular medicine Source Type: research
Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long?
Med Clin North Am. 2024 May;108(3):539-551. doi: 10.1016/j.mcna.2023.12.003. Epub 2024 Jan 9.ABSTRACTDual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is recommended for at least 6 and 12 months following percutaneous coronary intervention with drug-eluting stents among patients with stable ischemic heart disease and acute coronary syndrome, respectively. Additional exposure to antiplatelet therapy reduces ischemic events but also increases bleeding risk. Conversely, shorter durations of DAPT are preferred among those at high bleeding risk. Hence, decisions surrounding duration of DAPT after revasculariza...
Source: The Medical Clinics of North America - March 28, 2024 Category: General Medicine Authors: Khawaja Hassan Akhtar Usman Baber Source Type: research
Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long?
Med Clin North Am. 2024 May;108(3):539-551. doi: 10.1016/j.mcna.2023.12.003. Epub 2024 Jan 9.ABSTRACTDual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is recommended for at least 6 and 12 months following percutaneous coronary intervention with drug-eluting stents among patients with stable ischemic heart disease and acute coronary syndrome, respectively. Additional exposure to antiplatelet therapy reduces ischemic events but also increases bleeding risk. Conversely, shorter durations of DAPT are preferred among those at high bleeding risk. Hence, decisions surrounding duration of DAPT after revasculariza...
Source: The Medical Clinics of North America - March 28, 2024 Category: General Medicine Authors: Khawaja Hassan Akhtar Usman Baber Source Type: research
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
ConclusionAmong adults who underwent first-ever PCI for ACS, ticagrelor use in the DAPT was associated with a lower risk of MOF compared with clopidogrel. Our results support the use of ticagrelor in the DAPT from the perspective of bone health. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 27, 2024 Category: Endocrinology Source Type: research
Clinical Impacts of Urinary Neutrophil Gelatinase-Associated Lipocalin in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
CONCLUSIONS: Urinary NGAL could be a novel and informative biomarker for predicting subsequent renal and cardiovascular events in patients with CKD undergoing elective PCI.PMID:38538331 | DOI:10.1253/circj.CJ-24-0060 (Source: Circulation Journal)
Source: Circulation Journal - March 27, 2024 Category: Cardiology Authors: Yuta Ozaki Yusuke Uemura Akihito Tanaka Shogo Yamaguchi Takashi Okajima Takayuki Mitsuda Shinji Ishikawa Kenji Takemoto Toyoaki Murohara Masato Watarai Source Type: research
